Authors:
Buchholz, TA
Hill, BS
Tucker, SL
Frye, DK
Kuerer, HM
Buzdar, AU
McNeese, MD
Singletary, SE
Ueno, NT
Pusztai, L
Valero, V
Hortobagyi, GN
Citation: Ta. Buchholz et al., Factors predictive of outcome in patients with breast cancer refractory toneoadjuvant chemotherapy, CANCER J, 7(5), 2001, pp. 413-420
Citation: P. Jovari et L. Pusztai, Structure of disordered forms of selenium close to the melting point - art. no. 014205, PHYS REV B, 6401(1), 2001, pp. 4205
Citation: P. Jovari et al., The structure of liquid tetrachlorides CCl4, SiCl4, GeCl4, TiCl4, VCl4, and SnCl4, J CHEM PHYS, 114(18), 2001, pp. 8082-8090
Citation: L. Pusztai, Comparison between the structures of liquid water and (high- and low-density) amorphous ice, PHYS CHEM P, 2(12), 2000, pp. 2703-2706
Authors:
Madden, T
Tran, HT
Beck, D
Huie, R
Newman, RA
Pusztai, L
Wright, JJ
Abbruzzese, JL
Citation: T. Madden et al., Novel marine-derived anticancer agents: A phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients withadvanced solid tumors, CLIN CANC R, 6(4), 2000, pp. 1293-1301
Authors:
Pusztai, L
Holmes, FA
Fraschini, G
Hortobagyi, GN
Citation: L. Pusztai et al., Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy, CANC CHEMOT, 43(1), 1999, pp. 86-91
Authors:
Pusztai, L
Asmar, L
Smith, TL
Hortobagyi, GN
Citation: L. Pusztai et al., Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer, BREAST CANC, 55(1), 1999, pp. 1-8
Citation: G. Toth et al., Comment on "A new algorithm for reverse Monte Carlo simulations" [J. Chem.Phys. 109, 2624 (1998)], J CHEM PHYS, 111(12), 1999, pp. 5620-5621
Authors:
Boyer, CM
Pusztai, L
Wiener, JR
Xu, FJ
Dean, GS
Bast, BS
O'Briant, KC
Greenwald, M
DeSombre, KA
Bast, RC
Citation: Cm. Boyer et al., Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185, INT J CANC, 82(4), 1999, pp. 525-531
Citation: L. Pusztai et al., Physiologic and pathologic drug resistance in ovarian carcinoma - A hypothesis based on a clonal progression model, ACTA ONCOL, 37(7-8), 1998, pp. 629-640